SLS is trading 6.9% up now at $11.26 after investors react to newly amended executive employment and severance agreements that shift change-of-control benefits to lump-sum payments and accelerated equity vesting.
- In the biotech sector, these contract changes are often interpreted as preparation for a potential acquisition or strategic deal.
- The move comes as Wall Street closely monitors the imminent Phase 3 REGAL trial readout of GPS in acute myeloid leukemia (AML).
- SLS is continuing its multi-day breakout move despite broader market weakness.